Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Lower phosphorylated glycogen synthase kinase 3B levels in platelets of patients with schizophrenia: Increment by olanzapine treatment (2015)

  • Authors:
  • USP affiliated authors: GATTAZ, WAGNER FARID - FM
  • USP Schools: FM
  • DOI: 10.1007/s00406-014-0505-9
  • Subjects: ESQUIZOFRENIA (COMPLICAÇÕES); PLAQUETAS SANGUÍNEAS; ENZIMAS (DEFICIÊNCIA); FÁRMACOS
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    DOI or search this record in
    Informações sobre o DOI: 10.1007/s00406-014-0505-9 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Informações sobre o Citescore
  • Título: European Archives of Psychiatry and Clinical Neuroscience

    ISSN: 0940-1334

    Citescore - 2017: 2.93

    SJR - 2017: 1.574

    SNIP - 2017: 1.018


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FM2686764-10BCSEP 160 2015
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      FERREIRA, Aline Siqueira; RAPOSO, Nadia R. Barbosa; SALLET, Paulo Clemente; et al. Lower phosphorylated glycogen synthase kinase 3B levels in platelets of patients with schizophrenia: Increment by olanzapine treatment. European Archives of Psychiatry and Clinical Neuroscience, Berlin, v. 265, n. 2, p. 167-170, 2015. DOI: 10.1007/s00406-014-0505-9.
    • APA

      Ferreira, A. S., Raposo, N. R. B., Sallet, P. C., van de Bilt, M. T., Vieira, R. M., Gattaz, W. F., & Talib, L. L. (2015). Lower phosphorylated glycogen synthase kinase 3B levels in platelets of patients with schizophrenia: Increment by olanzapine treatment. European Archives of Psychiatry and Clinical Neuroscience, 265( 2), 167-170. doi:10.1007/s00406-014-0505-9
    • NLM

      Ferreira AS, Raposo NRB, Sallet PC, van de Bilt MT, Vieira RM, Gattaz WF, Talib LL. Lower phosphorylated glycogen synthase kinase 3B levels in platelets of patients with schizophrenia: Increment by olanzapine treatment. European Archives of Psychiatry and Clinical Neuroscience. 2015 ; 265( 2): 167-170.
    • Vancouver

      Ferreira AS, Raposo NRB, Sallet PC, van de Bilt MT, Vieira RM, Gattaz WF, Talib LL. Lower phosphorylated glycogen synthase kinase 3B levels in platelets of patients with schizophrenia: Increment by olanzapine treatment. European Archives of Psychiatry and Clinical Neuroscience. 2015 ; 265( 2): 167-170.

    Referências citadas na obra
    Frame S, Cohen P (2001) GSK3 takes center stage more than 20 years after its discovery. Biochem J 359:1–19
    Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3β in cellular signaling. Prog Neurobiol 65(4):391–426
    Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, Wayland M, Freeman T, Dudbridge F, Liley KS, Karp NA, Hester S, Tkachev D, Mimmack ML, Yolken RH, Webster MJ, Torrey EF, Bahn S (2004) Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9(7):684–697
    Engl J, Laimer M, Niderwanger A, Kranebiter M, Starzinger M, Pedrini MT, Fleischhacker WW, Patsch JR, Ebenbichler CF (2005) Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry 10(12):1089–1096
    King MK, Pardo M, Cheng Y, Downey K, Jope RS, Beurel E (2014) Glycogen synthase kinase-3 inhibitors: rescuers of cognitive impairments. Pharmacol Ther 141(1):1–12. doi: 10.1016/j.pharmthera.2013.07.010
    Lyman M, Lloyd DG, Ji X, Vizcaychipi MP, Ma D (2013) Neuroinflammation: the role and consequences. Neurosci Res 79:1–12. doi: 10.1016/j.neures.2013.10.004
    Jope RS, Yuskaitis CJ, Beurel E (2007) Glycogen synthase kinase-3 (GSK-3): inflammation, diseases and therapeutics. Neurochem Res 32(4–5):577–595
    Kozlovsky N, Belmaker RH, Agam G (2000) Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 157(5):831–833
    Beasley C, Cotter D, Khan N, Pollard C, Sheppard P, Varndell I, Lovestone S, Anderton B, Everall I (2001) Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci Lett 302(2–3):117–120
    Nadri C, Dean B, Scarr E, Agam G (2004) GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients. Schizophr Res 71(2–3):3773–3782
    Kozlovsky N, Regenold WT, Levine J, Rapoport A, Belmaker RH, Agam G (2004) GSK-3beta in cerebrospinal fluid of schizophrenia patients. J Neural Transm 111(8):1093–1098
    Nadri C, Kozlovsky N, Agam G, Bersudsky Y (2002) GSK-3 parameters in lymphocytes of schizophrenic patients. Psychiatry Res 112(1):51–57
    First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition with Psychotic Screen (SCID-I/P W/PSY SCREEN). Biometrics Research, New York State Psychiatric Institute, New York
    First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-Patient Edition (SCID-I/NP). Biometrics Research, New York State Psychiatric Institute, November, New York
    Forlenza OV, Torres CA, Talib LL, de Paula VJ, Joaquim HPG, Diniz BS, Gattaz WF (2010) Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer’s disease. J Psychiatr Res 45(2):220–224. doi: 10.1016/j.jpsychires.2010.06.002
    Emanian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004) Convergent evidence for impaired AKT-GSK3beta signaling in schizophrenia. Nat Genet 36(2):131–137
    Blasi G, Napolitano F, Ursini G, Di Giorgio A, Caforio G, Taurisano P, Fazio L, Gelao B, Atrotto MT, Colagiorgio L, Todarello G, Piva F, Papazacharias A, Masellis R, Mancini M, Porcelli A, Romano R, Rampino A, Quarto T, Giulietti M, Lipska BK, Kleinman JE, Popolizio T, Weinberger DR, Usiello A, Bertolino A (2013) Association of GSK-3β genetic variation with GSK-3β expression, prefrontal cortical thickness, prefrontal physiology, and schizophrenia. Am J Psychiatry 170(8):868–876. doi: 10.1176/appi.ajp.2012.12070908
    Alimohamad H, Rajakumar N, Seah Y, Rushlow W (2005) Antipsychotics alter the protein expression levels of β-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 57(5):533–542
    Kozlovsky N, Amar S, Belmaker RH, Agam G (2006) Psychotropic drugs affect Ser9-phosphorylated GSK-3 beta protein in rodent frontal cortex. Int J Neuropsychopharmacol 9(3):337–342
    Li X, Rosborough KM, Friedman AB, Zhu W, Roth KA (2007) Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int J Neuropsychopharmacol 10(1):7–19
    Ramirez SH, Fan S, Zhang M, Papugani A, Reichenbach N, Dykstra H, Mercer AJ, Tuma RF, Persidsky Y (2010) Inhibition of glycogen synthase kinase 3beta (GSK3beta) decreases inflammatory responses in brain endotelial cells. Am J Pathol 176(2):881–892. doi: 10.2353/ajpath.2010.090671
    Yuskaitis CJ, Jope RS (2009) Glycogen synthase kinase-3 regulates microglial migration, inflammation and inflammation-induced neurotoxicity. Cell Signal 21(2):264–273. doi: 10.1016/j.cellsig.2008.10.014
    Li X, Zhu W, Friedman AB, Rosborough K, Jope RS (2004) In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 29(8):1426–1431
    Hung AS, Tsui TY, Lam JC, Wai MS, Chan WM, Yew DT (2011) Serotonin and its receptors in the human CNS with new findings—a mini review. Curr Med Chem 18(34):5281–5288
    Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, Calligaro DO (1999) Olanzapine: a basic science update. Br J Psychiatry Suppl 37:36–40
    Muma NA, Singh RK, Vercillo MS, D´Souza DN, Zemaitatis B, Garcia F, Damjanoska KJ, Zhang Y, Battaglia G, Van de Kar LD (2007) Chronic olanzapine activates the Stat3 signal transduction pathway and alters expression of components of the 5-HT2A receptor signaling system in rat frontal cortex. Neuropharmacology 53(4):552–562
    Sing RK, Jia C, Garcia F, Carrasco GA, Battaglia G, Muma NA (2010) Activation of the JAK-STAT pathway by olanzapine is necessary for desensitization of serotonin2A receptor-stimulated phospholipase C signaling in rat frontal cortex but not serotonin2A receptor-stimulated hormone release. J Psychopharmacol 24(7):1079–1088
    Polter AM, Li X (2011) Glycogen synthase kinase-3 is an intermediate modulator of serotonin neurotransmission. Front Mol Neurosci 4(31):1–14. doi: 10.3389/fnmol.2011.00031